3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Ovarian Neoplasms
19
Breast Neoplasms
17
Fallopian Tube Neoplasms
12
Neoplasm Metastasis
10
Triple Negative Breast Neoplasms
9
Prostatic Neoplasms
7
Neoplasms
7
Endometrial Neoplasms
6
Small Cell Lung Carcinoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
3
Solid Tumors
3
Neuroendocrine Tumors
3
Metastatic Castration-resistant Prostate Cancer
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Glioma
3
Glioblastoma
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Recurrence
2
Pheochromocytoma
2
Paraganglioma
2
Osteosarcoma
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Cholangiocarcinoma
2
Interventions
pembrolizumab
2
durvalumab
2
Tretinoin
2
Paclitaxel
2
Oxaliplatin
2
Irinotecan
2
Chemoradiotherapy
2
Carboplatin
2
Capecitabine
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
relugolix
1
pexidartinib
1
pertuzumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
olaparib
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled